NO20082445L - Neuropeptid-2 reseptor-agonister - Google Patents
Neuropeptid-2 reseptor-agonisterInfo
- Publication number
- NO20082445L NO20082445L NO20082445A NO20082445A NO20082445L NO 20082445 L NO20082445 L NO 20082445L NO 20082445 A NO20082445 A NO 20082445A NO 20082445 A NO20082445 A NO 20082445A NO 20082445 L NO20082445 L NO 20082445L
- Authority
- NO
- Norway
- Prior art keywords
- neuropeptide
- receptor agonists
- obesity
- diabetes
- substituents
- Prior art date
Links
- 239000000018 receptor agonist Substances 0.000 title abstract 2
- 229940044601 receptor agonist Drugs 0.000 title abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57545—Neuropeptide Y
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74807105P | 2005-12-07 | 2005-12-07 | |
| US85524906P | 2006-10-30 | 2006-10-30 | |
| PCT/EP2006/068924 WO2007065808A2 (fr) | 2005-12-07 | 2006-11-27 | Agonistes du récepteur du neuropeptide-2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20082445L true NO20082445L (no) | 2008-09-03 |
Family
ID=37964711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20082445A NO20082445L (no) | 2005-12-07 | 2008-05-28 | Neuropeptid-2 reseptor-agonister |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7642244B2 (fr) |
| EP (1) | EP1962959B1 (fr) |
| JP (1) | JP5000663B2 (fr) |
| KR (1) | KR101059602B1 (fr) |
| AR (1) | AR057222A1 (fr) |
| AT (1) | ATE549350T1 (fr) |
| AU (1) | AU2006324076A1 (fr) |
| BR (1) | BRPI0619573A2 (fr) |
| CA (1) | CA2630649A1 (fr) |
| EC (1) | ECSP088511A (fr) |
| ES (1) | ES2381497T3 (fr) |
| IL (1) | IL191636A (fr) |
| MA (1) | MA30142B1 (fr) |
| NO (1) | NO20082445L (fr) |
| NZ (1) | NZ568772A (fr) |
| RU (2) | RU2430108C2 (fr) |
| TW (1) | TWI321474B (fr) |
| WO (1) | WO2007065808A2 (fr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010069242A (ko) * | 2000-09-05 | 2001-07-25 | 양우용 | 저주파 물리치료 겸용 혈압 강하기 |
| AU2006324076A1 (en) * | 2005-12-07 | 2007-06-14 | F. Hoffmann-La Roche Ag | Neuropeptide-2 receptor-agonists |
| US8299023B2 (en) * | 2008-09-17 | 2012-10-30 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists |
| CA2741921A1 (fr) * | 2008-11-05 | 2010-05-14 | F. Hoffmann-La Roche Ag | Agonistes du recepteur 2 de neuropeptide (y-2r) et leurs utilisations |
| EP2450374B9 (fr) | 2009-07-02 | 2016-11-23 | Takeda Pharmaceutical Company Limited | Peptide et son utilisation |
| JP2013505221A (ja) * | 2009-09-18 | 2013-02-14 | ノヴォ ノルディスク アー／エス | 長時間作用性ｙ２受容体アゴニスト |
| WO2011045232A2 (fr) * | 2009-10-13 | 2011-04-21 | F. Hoffmann-La Roche Ag | Agonistes du récepteur du neuropeptide-2 (y-2r) |
| RU2600440C3 (ru) | 2010-12-16 | 2021-12-10 | Ново Нордиск А/С | Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты |
| CA2822481A1 (fr) | 2011-01-03 | 2012-07-12 | F. Hoffmann-La Roche Ag | Composition pharmaceutique a base d'un complexe associant un anticorps anti-dig et de la digoxigenine conjuguee a un peptide |
| US10933120B2 (en) | 2012-03-22 | 2021-03-02 | Novo Nordisk A/S | Compositions of GLP-1 peptides and preparation thereof |
| EP3339328A1 (fr) | 2012-07-04 | 2018-06-27 | F. Hoffmann-La Roche AG | Anticorps anti-biotine et procédés d'utilisation |
| KR102090849B1 (ko) | 2012-07-04 | 2020-03-19 | 에프. 호프만-라 로슈 아게 | 공유 결합된 항원-항체 접합체 |
| EP2869837B1 (fr) | 2012-07-04 | 2016-09-14 | F. Hoffmann-La Roche AG | Anticorps anti-théophylline et procédés dýutilisation |
| AU2014261336B2 (en) | 2013-05-02 | 2019-02-28 | Novo Nordisk A/S | Oral dosing of GLP-1 compounds |
| US9085637B2 (en) | 2013-11-15 | 2015-07-21 | Novo Nordisk A/S | Selective PYY compounds and uses thereof |
| US10583172B2 (en) | 2013-11-15 | 2020-03-10 | Novo Nordisk A/S | HPYY(1-36) having a beta-homoarginine substitution at position 35 |
| JP6602304B2 (ja) | 2014-01-03 | 2019-11-06 | エフ．ホフマン−ラ ロシュ アーゲー | 共有結合で連結されたヘリカー−抗ヘリカー抗体コンジュゲートおよびその用途 |
| EP3089759B1 (fr) | 2014-01-03 | 2018-12-05 | F. Hoffmann-La Roche AG | Conjugués covalents entre un anticorps et une toxine polypeptidique |
| PL3089996T3 (pl) | 2014-01-03 | 2021-12-13 | F. Hoffmann-La Roche Ag | Dwuswoiste przeciwciała przeciw haptenowi/przeciw receptorowi występującemu w barierze krew-mózg, ich kompleksy i ich zastosowanie jako przenośniki wahadłowe występujące w barierze krew-mózg |
| MA41898A (fr) * | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| TWI694082B (zh) | 2015-06-12 | 2020-05-21 | 丹麥商諾佛 儂迪克股份有限公司 | 選擇性ｐｙｙ化合物及其用途 |
| BR112020014624A2 (pt) | 2018-02-02 | 2020-12-08 | Novo Nordisk A/S | Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante |
| MX2022005661A (es) | 2019-11-11 | 2022-09-07 | Boehringer Ingelheim Int | Agonistas del receptor npy2. |
| WO2022029231A1 (fr) | 2020-08-07 | 2022-02-10 | Boehringer Ingelheim International Gmbh | Agonistes du récepteur npy2 solubles |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5080891A (en) * | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| PL310897A1 (en) * | 1993-03-29 | 1996-01-08 | Univ Cincinnati | Analogues of yy peptide and their application |
| AUPO029096A0 (en) | 1996-06-05 | 1996-07-04 | Crc For Biopharmaceutical Research Pty Ltd | Npy y2 agonists |
| US6013633A (en) * | 1997-08-07 | 2000-01-11 | University Of Cincinnati | Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm |
| EP1202986B1 (fr) * | 1999-07-28 | 2005-10-12 | Ortho-McNeil Pharmaceutical, Inc. | Derives d'amines et d'amides utilises en tant que ligands pour le recepteur y5 du neuropeptide y, utile dans le traitement de l'obesite et d'autres troubles |
| EP2277527A3 (fr) | 2003-01-17 | 2011-08-31 | Ipsen Pharma | Analogues du peptide yy |
| CA2521784C (fr) | 2003-04-08 | 2012-03-27 | Yeda Research And Development Co. Ltd. | Medicaments pegyles reversibles |
| WO2005053726A1 (fr) | 2003-11-25 | 2005-06-16 | Bayer Pharmaceuticals Corporation | Agonistes selectifs du recepteur de neuropeptide y2 |
| WO2005080424A2 (fr) | 2004-02-23 | 2005-09-01 | Rheoscience A/S | Analogues du peptide yy |
| US7410949B2 (en) * | 2005-01-18 | 2008-08-12 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof |
| WO2006091505A2 (fr) | 2005-02-24 | 2006-08-31 | Bayer Pharmaceuticals Corporation | Agonistes du recepteur y de neuropeptide |
| AU2006324076A1 (en) * | 2005-12-07 | 2007-06-14 | F. Hoffmann-La Roche Ag | Neuropeptide-2 receptor-agonists |
| WO2007085887A1 (fr) | 2006-01-27 | 2007-08-02 | Pfizer Products Inc. | Agonistes du pyy et leurs utilisations |
-
2006
- 2006-11-27 AU AU2006324076A patent/AU2006324076A1/en not_active Abandoned
- 2006-11-27 JP JP2008543768A patent/JP5000663B2/ja not_active Expired - Fee Related
- 2006-11-27 EP EP06830133A patent/EP1962959B1/fr active Active
- 2006-11-27 WO PCT/EP2006/068924 patent/WO2007065808A2/fr not_active Ceased
- 2006-11-27 NZ NZ568772A patent/NZ568772A/en not_active IP Right Cessation
- 2006-11-27 BR BRPI0619573-3A patent/BRPI0619573A2/pt not_active IP Right Cessation
- 2006-11-27 AT AT06830133T patent/ATE549350T1/de active
- 2006-11-27 CA CA002630649A patent/CA2630649A1/fr not_active Abandoned
- 2006-11-27 KR KR1020087016291A patent/KR101059602B1/ko not_active Expired - Fee Related
- 2006-11-27 ES ES06830133T patent/ES2381497T3/es active Active
- 2006-11-27 RU RU2008127265/04A patent/RU2430108C2/ru not_active IP Right Cessation
- 2006-12-01 US US11/607,230 patent/US7642244B2/en not_active Expired - Fee Related
- 2006-12-04 TW TW095145032A patent/TWI321474B/zh not_active IP Right Cessation
- 2006-12-05 AR ARP060105368A patent/AR057222A1/es active IP Right Grant
-
2008
- 2008-05-22 IL IL191636A patent/IL191636A/en not_active IP Right Cessation
- 2008-05-28 NO NO20082445A patent/NO20082445L/no not_active Application Discontinuation
- 2008-06-06 EC EC2008008511A patent/ECSP088511A/es unknown
- 2008-07-01 MA MA31085A patent/MA30142B1/fr unknown
-
2009
- 2009-08-06 US US12/536,688 patent/US8268784B2/en not_active Expired - Fee Related
-
2011
- 2011-02-15 RU RU2011105310/04A patent/RU2011105310A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US8268784B2 (en) | 2012-09-18 |
| ECSP088511A (es) | 2008-07-30 |
| WO2007065808A3 (fr) | 2007-08-02 |
| ES2381497T3 (es) | 2012-05-28 |
| CA2630649A1 (fr) | 2007-06-14 |
| JP5000663B2 (ja) | 2012-08-15 |
| EP1962959A2 (fr) | 2008-09-03 |
| AR057222A1 (es) | 2007-11-21 |
| IL191636A (en) | 2012-10-31 |
| ATE549350T1 (de) | 2012-03-15 |
| US20100137223A1 (en) | 2010-06-03 |
| RU2011105310A (ru) | 2012-08-20 |
| IL191636A0 (en) | 2008-12-29 |
| KR20080082672A (ko) | 2008-09-11 |
| AU2006324076A1 (en) | 2007-06-14 |
| US20070135351A1 (en) | 2007-06-14 |
| BRPI0619573A2 (pt) | 2011-10-04 |
| TWI321474B (en) | 2010-03-11 |
| KR101059602B1 (ko) | 2011-08-25 |
| RU2008127265A (ru) | 2010-01-20 |
| MA30142B1 (fr) | 2009-01-02 |
| RU2430108C2 (ru) | 2011-09-27 |
| US7642244B2 (en) | 2010-01-05 |
| NZ568772A (en) | 2010-05-28 |
| WO2007065808A2 (fr) | 2007-06-14 |
| TW200806311A (en) | 2008-02-01 |
| JP2009518349A (ja) | 2009-05-07 |
| EP1962959B1 (fr) | 2012-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20082445L (no) | Neuropeptid-2 reseptor-agonister | |
| NO20073664L (no) | Peptider med neuropeptid-2-reseptor (Y2R) agonist aktivitet | |
| NO20083863L (no) | Pyrazoler som 11-beta-hsd-1 | |
| NO20074872L (no) | Pyrazoler | |
| NO20092033L (no) | Nye forbindelser | |
| NO20080789L (no) | 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid | |
| NO20070176L (no) | Nye fluorglykosidderivater av pyrazoler, medikamenter inneholdende disse forbindelsene og anvendelse derav | |
| WO2007082808A3 (fr) | Thiazoles en tant qu'inhibiteurs de 11 beta-hsd1 | |
| NO20074703L (no) | Antibakterielle piperidinderivater | |
| IL187005A0 (en) | Diacylglycerol acyltransferase inhibitors | |
| TW200621762A (en) | Novel compounds | |
| EA200970585A1 (ru) | Бензамидные производные как агонисты ер-рецепторов | |
| MX2007010532A (es) | Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii. | |
| WO2007128480A3 (fr) | Thioglycosides au titre de principes actifs pharmaceutiques | |
| NO20070224L (no) | 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav | |
| NO20066055L (no) | Pyridinderivater | |
| WO2007087548A3 (fr) | Composés chimiques | |
| NO20084049L (no) | Forbindelser med forsterket ampa receptor og anvendelse derav i medisin | |
| NO20082496L (no) | Pyrazinderivater | |
| NO20081844L (no) | Terapeutiske forbindelser | |
| NO20065904L (no) | Terapeutiske forbindelser | |
| NO20071137L (no) | Nye piperidinderivater for behandling av depresjon | |
| WO2010052144A3 (fr) | Agonistes du récepteur 2 de neuropeptide (y-2r) et leurs utilisations | |
| IN2012DN03042A (fr) | ||
| NO20063576L (no) | 1,3-dioksanederivativer og analoge forbindelser for behandling av fedme og diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |